ATLANTA, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that four ILUVIEN® data sets will be presented during the 2017 Annual Meeting of the Retina Society to be held October 5 through 8 at the Fairmont Copley Plaza Hotel in Boston.

"We are excited to see new data and analysis from both real world clinical experience and our pivotal FAME Study being presented at the Retina Society this year.  We believe the new data being presented validates the key value of ILUVIEN’s continuous microdosing and unique ability to treat diabetic macular edema consistently every day," said Dan Myers, CEO of Alimera. "We are particularly gratified to share data from the USER (U.S. Retrospective Chart Review in Patients Receiving ILUVIEN) Study as it demonstrates ILUVIEN’s ability to provide maintained or improved visual acuity with a reduced treatment frequency and the effectiveness of the U.S. label to help physicians mitigate intraocular pressure responses."

Scheduled to be presented at the podium are:

  • Thursday, Oct. 5 – 4:55 p.m. – “Area Under the Curve (AUC) Analysis of Visual Outcomes with the Fluocinolone Acetonide Implant and with Ranibizumab and Deferred Laser Over 36 Months,” by Craig Greven, M.D.
  • Sunday, Oct. 8 – 8:10 a.m. – “Real World Outcomes with the Fluocinolone Acetonide (FAc) 0.2 g/day Implant for Diabetic Macular Edema: The USER Study,” by Christopher Riemann, M.D.             

The following two posters are included in Poster Session II – Saturday, Oct. 7, 1:15 PM – 2:15 p.m.:

  • “Year 3 Visual Acuity Response in Early Nonresponders to 0.2 ug/day Fluocinolone Acetonide Implants: FAME Study Post Hoc Analysis,” by Daniel Kiernan, M.D.
  • “Fluocinolone Acetonide Intravitreal Implant in Treatment Experienced Eyes for Diabetic Macular Edema (DME): One-year Results,” by Sumit Shah, M.D.


ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit

For press inquiries:
Katie Brazel
for Alimera Sciences

For investor inquiries:
CG Capital
for Alimera Sciences

Primary Logo